Surrey Heartlands

Joint Formulary & PAD

Mycophenolate mofetil - Scleritis

You are here : Home > Formulary Search > Mycophenolate mofetil - Scleritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Capsules
  • Gastro-resistant tablets
  • Oral suspension
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Un
Restrictions / Comments :

Documentation

Shared Care
Shared Care Request letter (Specialist to Primary Care Prescriber) - National Shared Care - Appendix 1
Shared Care
Shared Care Agreement Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 2
Shared Care
Shared Care Refusal Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 3
Webpage
MHRA Drug Safety Update : Mycophenolate mofetil: pure red cell aplasia
Webpage
MHRA Drug Safety Update : Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

PAD Profile

ChemicalSubstance :
Mycophenolate mofetil
Indication :
Scleritis
Group Name :
Keywords :
mycophenolic sodium, mycophenolic acid, mycophenolate sodium
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5

Other Indications

Below are listed other indications that Mycophenolate mofetil is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Scleritis.

Committee Recommendations (1)

07 Dec 22 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol (with local adaptations) for mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)